novo nordisk - Search News

News

Novo Nordisk, copycat and weight loss

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back its sales.

This is Money on MSN · 4h

Ozempic maker Novo Nordisk set for slimmer sales amid surge in copycat weight-loss drugs

Novo Nordisk, which also makes Wegovy, fell victim to 'compounding' - a practice in the US that allows pharmacies to produce replicas.

NJBIZ · 1d

Novo Nordisk seeks FDA approval for Wegovy weight loss pill

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 for obesity.

Novo Nordisk, Wegovy

Reuters on MSN · 12h

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

Investopedia on MSN · 15h

Novo Nordisk Stock Jumps Despite Full-Year Outlook Cut

U.S.-listed shares of Novo Nordisk are jumping in premarket trading Wednesday even as the Danish pharmaceutical giant lowered its full-year outlook.

Bloomberg on MSN · 16h

Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential

Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving the way for a sales rebound later this year.

5don MSN

Novo Nordisk Says FDA Accepted New Drug Application for Wegovy Pill

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

10hon MSN

Why Novo Nordisk Stock Popped After Earnings

Novo Nordisk reports its results in Danish kroner (DKK) rather than U.S. dollars. Sales grew 19% year over year to 78.1 ...

The Economist7h

Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

The Cardiology Advisor9h

Novo Nordisk Partners With Telehealth Platforms to Expand Wegovy Access

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...

12hon MSN

Novo Nordisk Predicts Strong Second Half

The immediate market reaction to Novo Nordisk's earnings report was a positive one. As of 7 a.m. EDT, a few hours after the earnings release, shares of the drugmaker were up by about 5%. In short, the ...